Pure Biologics S.A. (WSE:PUR)

Poland flag Poland · Delayed Price · Currency is PLN
4.286
+0.196 (4.79%)
Jan 5, 2026, 5:03 PM CET
-74.73%
Market Cap34.99M
Revenue (ttm)n/a
Net Income (ttm)-17.93M
Shares Out8.16M
EPS (ttm)-4.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume148,621
Average Volume50,443
Open4.300
Previous Close4.090
Day's Range3.940 - 4.580
52-Week Range3.100 - 17.660
Beta0.72
RSI52.72
Earnings DateApr 29, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified apta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 7
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PUR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.